Q3 2024 Crinetics Pharmaceuticals Inc Earnings Call Transcript

Nov 12, 2024 / 09:30 PM GMT

Release Date Price: €56 (+0.90%)

Transcript 10-Q8-K

Key Points

Positve

Crinetics Pharmaceuticals Inc (CRNX) has submitted its first NDA for paltusotine, a next-generation therapy for acromegaly, and anticipates FDA filing notification in December.
The company is preparing for the anticipated launch of paltusotine by building commercial capabilities and engaging with payers for formulary placement.
Crinetics Pharmaceuticals Inc (CRNX) has a strong financial position with approximately $1.4 billion in cash and investments, projected to fund operations into 2029.
The company is advancing a robust pipeline with multiple candidates, including CRN 9,682, a novel nonpeptide drug conjugate for cancer treatment.
Positive results from a phase two study for carcinoid syndrome were reported, with plans to start a phase three trial on schedule.

Negative

There were no revenues for the quarter ended September 30, 2024, compared to $0.3 million for the same period in 2023.
Research and development expenses increased to $61.9 million for the quarter, up from $43.8 million in the same period in 2023, driven by higher personnel costs and manufacturing activities.
General and administrative expenses rose to $25.9 million for the quarter, compared to $15.5 million in the same period in 2023, due to higher personnel costs and commercial planning activities.
Net loss for the quarter was $76.8 million, compared to a net loss of $57.5 million for the same period in 2023.
The company anticipates increased R&D and SG&A expenses as it prepares for the potential launch of paltusotine and initiates multiple phase three studies.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

CRNX.OQ - Crinetics Pharmaceuticals Inc
Q3 2024 Crinetics Pharmaceuticals Inc Earnings Call
Nov 12, 2024 / 09:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
To all sites on hold. We appreciate your patience and ask that you please continue to stand by your program will begin in approximately one minute.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Yes, please.

--------------------------------------------------------------------------------
Unidentified_3 [3]
--------------------------------------------------------------------------------
Please stand by your program is about to begin. If you need audio assistance during today's program, please press star zero.

Welcome to the

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.